Cite
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
MLA
Choueiri, Toni K., et al. “Cabozantinib versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update.” European Journal of Cancer (Oxford, England : 1990), vol. 94, May 2018, pp. 115–25. EBSCOhost, https://doi.org/10.1016/j.ejca.2018.02.012.
APA
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., Dakhil, S., Feldman, D. R., Mangeshkar, M., Scheffold, C., George, D., & Morris, M. J. (2018). Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European Journal of Cancer (Oxford, England : 1990), 94, 115–125. https://doi.org/10.1016/j.ejca.2018.02.012
Chicago
Choueiri, Toni K, Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. 2018. “Cabozantinib versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update.” European Journal of Cancer (Oxford, England : 1990) 94 (May): 115–25. doi:10.1016/j.ejca.2018.02.012.